Trial Profile

An expanded access study of AXO-AAV-GM2 gene therapy in patients with infantile Tay-Sachs disease

Status: Active, no longer recruiting

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 28 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cobnabexagene anvuparvovec (Primary) ; Cobnabexagene anvuparvovec (Primary) ; Cobnabexagene anvuparvovec (Primary)
Indications Tay-Sachs disease
Focus Expanded access; First in man; Therapeutic Use

Most Recent Events

11 Aug 2020 According to an Axovant Gene Therapies media release, data was presented at the 23rd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT).
07 May 2020 According to an Axovant Gene Therapies media release, data from this will be presented at the 23rd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT).
31 Oct 2019 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com